LSA
BLCM

L & S Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

L & S Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,073
Closed -$251K – 343
2018
Q3 		$251K Sell
4,073
-4,240
-51% -$287K 0.03% 281
2018
Q2 		$613K Buy
+8,313
New +$648K 0.1% 186

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

L & S Advisors's BLCM Position: Q4 2018 in Review

L & S Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2018, closing a stake of 4,073 shares — an estimated $251K sold.

L & S Advisors first reported a position in BLCM in Q2 2018 and held it in 2 quarters. The position peaked at $613K in Q2 2018. 92 funds tracked by Wall St. Rank hold BLCM as of Q4 2018.

  • L & S Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • L & S Advisors sold 4,073 Bellicum Pharmaceuticals, Inc. shares in Q4 2018, an estimated $251K.
  • L & S Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
  • L & S Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $613K in Q2 2018.
  • 92 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2018.

Based on L & S Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.